{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:52:32Z","timestamp":1790315552877,"version":"4.1.0"},"reference-count":32,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","award":["G17249"],"award-info":[{"award-number":["G17249"]}],"id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP 1020327"],"award-info":[{"award-number":["OPP 1020327"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001125","name":"GAVI Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["WI222797"],"award-info":[{"award-number":["WI222797"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2021,11,29]]},"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Introducing pneumococcal conjugate vaccine (PCV) in many low-income countries has contributed to reductions in global childhood deaths caused by <jats:italic>Streptococcus pneumoniae<\/jats:italic>. Many low-income countries, however, will soon reach an economic status leading to transition from Gavi, the Vaccine Alliance vaccine funding support and then face increased expenditure to continue PCV programmes. Evaluating the cost-effectiveness of PCV in low-income countries will inform such country decisions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used empiric data on the costs of vaccine delivery and pneumococcal disease and PCV programme impact on disease among children less than 5\u2009years old in The Gambia. We used the UNIVAC cost-effectiveness modelling tool to compare the impact and cost-effectiveness of pneumococcal conjugate vaccination to no vaccination over 20 birth cohorts starting in 2011. We calculated costs per disability-adjusted-life-year (DALY) averted from government and societal perspectives and undertook scenario and probabilistic sensitivity analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We projected that, over 20 years, PCV in The Gambia could avert 117\u2009000 total disease episodes in children less than 5\u2009years old, including outpatient and hospitalised pneumonia, pneumococcal sepsis and meningitis (including sequelae). Vaccination could avert 9000 outpatient pneumonia visits, 88\u2009000 hospitalisations and 3300 deaths due to pneumonia, meningitis and sepsis. Approximately 100\u2009000 DALYs are expected to be averted. Averted visits and hospitalisations represent US$4\u2009million in healthcare costs expected to be saved by the government and US$7.3\u2009million if household costs are included. The cost of the vaccination programme is estimated at US$2 million. In the base scenario, most alternative scenarios and nearly 90% of the probabilistic scenarios, pneumococcal vaccination is cost saving in The Gambia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Pneumococcal conjugate vaccination is expected to generate substantial health gains and is likely to be cost saving in The Gambia. Policymakers in similar settings should be confident to maintain their PCV programmes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgh-2021-007211","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T11:21:28Z","timestamp":1639653688000},"page":"e007211","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Pneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implications"],"prefix":"10.1136","volume":"6","author":[{"given":"Clint","family":"Pecenka","sequence":"first","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effua","family":"Usuf","sequence":"additional","affiliation":[{"name":"Disease Control and Elimination, Medical Research Council The Gambia, Banjul, Gambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Hossain","sequence":"additional","affiliation":[{"name":"Disease Control and Elimination, Medical Research Council The Gambia, Banjul, Gambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Sambou","sequence":"additional","affiliation":[{"name":"Ministry of Health, Government of the Gambia, Banjul, Gambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Vodicka","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Atherly","sequence":"additional","affiliation":[{"name":"Center for Vaccine Innovation and Access, PATH, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Mackenzie","sequence":"additional","affiliation":[{"name":"Disease Control and Elimination, MRC Unit The Gambia at LSHTM, Banjul, Gambia"},{"name":"London School of Hygiene & Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"2025073014325833000_6.12.e007211.1","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1016\/S2214-109X(18)30247-X","article-title":"Burden of streptococcus pneumoniae and haemophilus influenzae type B disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15","volume":"6","author":"Wahl","year":"2018","journal-title":"Lancet Glob Health"},{"key":"2025073014325833000_6.12.e007211.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71876-6"},{"key":"2025073014325833000_6.12.e007211.3","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-016-0053-4"},{"key":"2025073014325833000_6.12.e007211.4","unstructured":"The World Bank Group . GDP per capita (current US$). World bank open data, 2020. Available: https:\/\/data.worldbank.org\/indicator\/NY.GNP.PCAP.CD?locations=GM [Accessed 30 Dec 2020]."},{"key":"2025073014325833000_6.12.e007211.5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001161"},{"key":"2025073014325833000_6.12.e007211.6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1473-3099(16)00054-2","article-title":"Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in the Gambia: a population-based surveillance study","volume":"16","author":"Mackenzie","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2025073014325833000_6.12.e007211.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30321-3"},{"key":"2025073014325833000_6.12.e007211.8","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(20)30880-X","article-title":"Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in the Gambia: 10 years of population-based surveillance","volume":"21","author":"Mackenzie","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2025073014325833000_6.12.e007211.9","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/S0140-6736(18)33005-8","article-title":"Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study","volume":"393","author":"Hammitt","year":"2019","journal-title":"Lancet"},{"key":"2025073014325833000_6.12.e007211.10","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1016\/S2214-109X(18)30491-1","article-title":"Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis","volume":"7","author":"Silaba","year":"2019","journal-title":"Lancet Glob Health"},{"key":"2025073014325833000_6.12.e007211.11","unstructured":"International Vaccine Access Center (IVAC) . Johns hopkins bloomberg school of public health. VIEW-hub report: global vaccine introduction and implementation. Baltimore, MD: Johns Hopkins Bloomberg School of Public Health, 2019"},{"key":"2025073014325833000_6.12.e007211.12","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s40273-016-0439-3","article-title":"Cost effectiveness of pneumococcal vaccination in children in low- and middle-income countries: a systematic review","volume":"34","author":"Saokaew","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"2025073014325833000_6.12.e007211.13","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.1016\/j.vaccine.2016.10.051","article-title":"Cost-effectiveness analysis of pneumococcal vaccination for infants in China","volume":"34","author":"Maurer","year":"2016","journal-title":"Vaccine"},{"key":"2025073014325833000_6.12.e007211.14","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.vaccine.2016.12.070","article-title":"Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia","volume":"35","author":"Sundaram","year":"2017","journal-title":"Vaccine"},{"key":"2025073014325833000_6.12.e007211.15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067324"},{"key":"2025073014325833000_6.12.e007211.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.12.122"},{"key":"2025073014325833000_6.12.e007211.17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-260"},{"key":"2025073014325833000_6.12.e007211.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-019-7423-8","article-title":"Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: results from a quasi-experimental evaluation","volume":"19","author":"Kebede","year":"2019","journal-title":"BMC Public Health"},{"key":"2025073014325833000_6.12.e007211.19","doi-asserted-by":"crossref","first-page":"e644","DOI":"10.1016\/S2214-109X(18)30562-X","article-title":"Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya","volume":"7","author":"Ojal","year":"2019","journal-title":"Lancet Glob Health"},{"key":"2025073014325833000_6.12.e007211.20","unstructured":"Gavi, The Vaccine Alliance . Co-financing policy. Gavi, the vaccine alliance, 2020. Available: https:\/\/www.gavi.org\/programmes-impact\/programmatic-policies\/co-financing-policy [Accessed 22 Sep 2020]."},{"key":"2025073014325833000_6.12.e007211.21","unstructured":"Gavi, The Vaccine Alliance . Product information for vaccines and cold chain equipment, 2020. Available: https:\/\/www.gavi.org\/our-alliance\/market-shaping\/product-information-vaccines-cold-chain-equipment [Accessed 22 Sep 2020]."},{"key":"2025073014325833000_6.12.e007211.22","unstructured":"Gavi, The Vaccine Alliance . Country hub. Gavi, the vaccine alliance, 2020. Available: https:\/\/www.gavi.org\/programmes-impact\/country-hub [Accessed 21 Aug 2019]."},{"key":"2025073014325833000_6.12.e007211.23","unstructured":"PAHO\/WHO . Provac toolkit | providing tools to support vaccine decision making at country-level, 2021. Available: https:\/\/www.paho.org\/provac-toolkit\/ [Accessed 20 Apr 2021]."},{"key":"2025073014325833000_6.12.e007211.24","unstructured":"IDSI Health . Bill and Melinda gates foundation. Gates reference case. Available: https:\/\/www.idsihealth.org\/wp-content\/uploads\/2016\/05\/Gates-Reference-case-what-it-is-how-to-use-it.pdf [Accessed 20 Oct 2021]."},{"key":"2025073014325833000_6.12.e007211.25","unstructured":"The World Bank Group . World development indicators. DataBank, 2020. Available: https:\/\/databank.worldbank.org\/reports.aspx?source=world-development-indicators [Accessed 22 Sep 2020]."},{"key":"2025073014325833000_6.12.e007211.26","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.10.080796"},{"key":"2025073014325833000_6.12.e007211.27","unstructured":"Global Burden of Disease Collaborative Network . Global burden of disease study 2016 (GBD 2016) disability weights, 2017. Available: http:\/\/ghdx.healthdata.org\/record\/ihme-data\/gbd-2016-disability-weights [Accessed 22 Sep 2020]."},{"key":"2025073014325833000_6.12.e007211.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107280","article-title":"Coverage and timing of children's vaccination: an evaluation of the expanded programme on immunisation in the Gambia","volume":"9","author":"Scott","year":"2014","journal-title":"PLoS One"},{"key":"2025073014325833000_6.12.e007211.29","unstructured":"The Government of Gambia . GAVI alliance annual progress report 2013. Gavi, The Vaccine Alliance, 2014."},{"key":"2025073014325833000_6.12.e007211.30","unstructured":"Immunization Costing Action Network (ICAN) . Immunization delivery cost catalog, 2019. Available: http:\/\/immunizationeconomics.org\/ican-idcc [Accessed 22 Sep 2020]."},{"key":"2025073014325833000_6.12.e007211.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60195-0"},{"key":"2025073014325833000_6.12.e007211.32","unstructured":"Pan American Health Organization (PAHO) . Where we work. Available: https:\/\/www.paho.org\/provac-toolkit\/about-us\/where-we-work\/ [Accessed 22 Sep 2020]."}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2021-007211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T21:33:18Z","timestamp":1753911198000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2021-007211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,16]]},"published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1136\/bmjgh-2021-007211"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2021-007211","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]}}}